Literature DB >> 20473713

Detection of disease specific sialoglycoconjugate specific antibodies in bronchoalveolar lavage fluid of non-small cell lung cancer patients.

Sangeeta Mehta1, Rakhee Chhetra, Radhika Srinivasan, Suresh C Sharma, Digambar Behera, Sujata Ghosh.   

Abstract

In this study, we report the presence of significantly higher level of GM3 specific IgG antibodies (IgG(TL)) in the bronchoalveolar lavage fluid obtained from tumor bearing lung of non-small cell lung cancer (NSCLC) patients as compared to other non-neoplastic controls. The antibodies were isolated using DEAE-cellulose anion exchange chromatography and molecular weight of the subunits of IgG(TL) was confirmed in SDS-PAGE. IgG(TL) revealed high specificity to GM3 and the IgG distribution was confined to IgG1. Furthermore, IgG(TL) showed strong reactivity with NSCLC cell lines as well as the tissue biopsies and cells obtained from fine needle aspirations of NSCLC patients. A 66 kDa membrane glycoprotein of NSCLC cell lines was found to interact specifically with IgG(TL), the intensity of which was drastically reduced in presence of GM3. Further, binding of Maackia amurensis agglutinin [specific for NeuAcalpha(2-->3)Gal unit , the same disaccharide unit also known to be present in GM3] to the 66 kDa band confirmed it to be a sialoglycoprotein in nature. IgG(TL) could not show any reactivity to alkaline borohydrate treated or periodate oxidised membrane fractions, suggesting the probable involvement of the carbohydrate moiety of the 66 kDa glycoprotein in the interaction with IgG(TL). Thus, the 66 kDa sialoglycoprotein seems to be the NSCLC specific sialoglycoconjugate. Taken together, IgG(TL) antibodies may have the potential to serve as a unique probe for detail investigation of NSCLC specific cell surface sialoglycoconjugate. Further, due to high specificity of IgG(TL) to GM3, it may be possible to develop a simple alternative diagnostic approach (GM3-ELISA) for NSCLC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20473713     DOI: 10.1007/s10719-010-9294-1

Source DB:  PubMed          Journal:  Glycoconj J        ISSN: 0282-0080            Impact factor:   2.916


  35 in total

1.  Serum sialyl Lewis X-i antigen in lung adenocarcinoma and idiopathic pulmonary fibrosis.

Authors:  H Satoh; H Ishikawa; Y T Yamashita; M Ohtsuka; K Sekizawa
Journal:  Thorax       Date:  2002-03       Impact factor: 9.139

2.  Identification of glycoproteins on nitrocellulose membranes and gels.

Authors:  D J Thornton; I Carlstedt; J K Sheehan
Journal:  Mol Biotechnol       Date:  1996-04       Impact factor: 2.695

Review 3.  Lectins as bioactive plant proteins: a potential in cancer treatment.

Authors:  Elvira González De Mejía; Valentin I Prisecaru
Journal:  Crit Rev Food Sci Nutr       Date:  2005       Impact factor: 11.176

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 5.  Tumor-associated carbohydrate antigens.

Authors:  S Hakomori
Journal:  Annu Rev Immunol       Date:  1984       Impact factor: 28.527

Review 6.  Non small cell lung cancer (NSCLC): current status and future prospects.

Authors:  A K Pathak; M Bhutani; A Mohan; R Guleria; S Bal; V Kochupillai
Journal:  Indian J Chest Dis Allied Sci       Date:  2004 Jul-Sep

7.  Mild alkaline borohydride treatment of glycoproteins-a method for liberating both N- and O-linked carbohydrate chains.

Authors:  S Ogata; K O Lloyd
Journal:  Anal Biochem       Date:  1982-01-15       Impact factor: 3.365

8.  Reactive antibodies in the bronchial washings of lung cancer patients.

Authors:  E Paluch; H L Ioachim
Journal:  Int J Cancer       Date:  1979-01-15       Impact factor: 7.396

9.  Spectral karyotyping detects chromosome damage in bronchial cells of smokers and patients with cancer.

Authors:  Marileila Varella-Garcia; Lin Chen; Roger L Powell; Fred R Hirsch; Timothy C Kennedy; Robert Keith; York E Miller; John D Mitchell; Wilbur A Franklin
Journal:  Am J Respir Crit Care Med       Date:  2007-06-28       Impact factor: 21.405

Review 10.  Lectin of Concanavalin A as an anti-hepatoma therapeutic agent.

Authors:  Huan-Yao Lei; Chih-Peng Chang
Journal:  J Biomed Sci       Date:  2009-01-19       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.